[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE60239881D1 - Verfahren zur identifikation von polypeptid-antigenen im zusammenhang mit störungen durch aberrante zellproliferation - Google Patents

Verfahren zur identifikation von polypeptid-antigenen im zusammenhang mit störungen durch aberrante zellproliferation

Info

Publication number
DE60239881D1
DE60239881D1 DE60239881T DE60239881T DE60239881D1 DE 60239881 D1 DE60239881 D1 DE 60239881D1 DE 60239881 T DE60239881 T DE 60239881T DE 60239881 T DE60239881 T DE 60239881T DE 60239881 D1 DE60239881 D1 DE 60239881D1
Authority
DE
Germany
Prior art keywords
antibodies
mitotic
cell
polypeptide
cdc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60239881T
Other languages
English (en)
Inventor
Arthur D Levinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE60239881D1 publication Critical patent/DE60239881D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DE60239881T 2001-09-05 2002-09-04 Verfahren zur identifikation von polypeptid-antigenen im zusammenhang mit störungen durch aberrante zellproliferation Expired - Lifetime DE60239881D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31750401P 2001-09-05 2001-09-05
PCT/US2002/028176 WO2003020909A2 (en) 2001-09-05 2002-09-04 Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders

Publications (1)

Publication Number Publication Date
DE60239881D1 true DE60239881D1 (de) 2011-06-09

Family

ID=23233944

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60239881T Expired - Lifetime DE60239881D1 (de) 2001-09-05 2002-09-04 Verfahren zur identifikation von polypeptid-antigenen im zusammenhang mit störungen durch aberrante zellproliferation

Country Status (17)

Country Link
EP (1) EP1432446B1 (de)
JP (2) JP5224632B2 (de)
KR (3) KR20100061863A (de)
CN (2) CN1578673A (de)
AT (1) ATE506965T1 (de)
AU (1) AU2002332838B2 (de)
BR (1) BR0212641A (de)
CA (1) CA2457541C (de)
DE (1) DE60239881D1 (de)
DK (1) DK1432446T3 (de)
HU (1) HUP0500617A3 (de)
IL (2) IL160659A0 (de)
MX (1) MXPA04002084A (de)
NZ (1) NZ531515A (de)
PL (1) PL374363A1 (de)
WO (1) WO2003020909A2 (de)
ZA (1) ZA200401751B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088387B2 (en) * 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
HUE054074T2 (hu) * 2003-05-20 2021-08-30 Immunogen Inc Tökéletesített, új maytansinoidokat tartalmazó citotoxikus szerek
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
CN101087611B (zh) * 2003-10-10 2019-04-23 伊缪诺金公司 用经不可切割接头连接的细胞结合剂美登木素生物碱偶联物靶向特定细胞群的方法、所述偶联物和制备所述偶联物的方法
JP5555223B2 (ja) * 2008-04-02 2014-07-23 マクロジェニクス，インコーポレーテッド ＨＥＲ２／ｎｅｕ特異的抗体およびその使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2026147C (en) * 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
DE60020529T2 (de) * 1999-03-01 2006-04-27 Genentech Inc., San Francisco Antikörper zur krebsbehandlung und -diagnose
NZ518477A (en) * 1999-10-29 2004-10-29 Genentech Inc Isolated anti-prostate stem cell antigen (PSCA) antibodies that internalise upon binding to PSCA on a mammalian cell, including a PSCA-expressing tumour cell, in vivo
CA2397416A1 (en) * 2000-01-26 2001-08-02 Jonathan Cohen A system for developing assays for personalized medicine

Also Published As

Publication number Publication date
KR20040044850A (ko) 2004-05-31
KR20100061863A (ko) 2010-06-09
JP2005517155A (ja) 2005-06-09
PL374363A1 (en) 2005-10-17
BR0212641A (pt) 2005-04-12
HUP0500617A2 (hu) 2005-10-28
NZ531515A (en) 2007-11-30
IL160659A (en) 2011-07-31
CN101446590A (zh) 2009-06-03
JP5224632B2 (ja) 2013-07-03
WO2003020909A2 (en) 2003-03-13
ZA200401751B (en) 2005-07-27
MXPA04002084A (es) 2004-06-07
CA2457541C (en) 2013-01-08
JP2010280691A (ja) 2010-12-16
KR20090104925A (ko) 2009-10-06
HUP0500617A3 (en) 2012-05-02
EP1432446A2 (de) 2004-06-30
EP1432446B1 (de) 2011-04-27
DK1432446T3 (da) 2011-07-18
CN1578673A (zh) 2005-02-09
ATE506965T1 (de) 2011-05-15
CA2457541A1 (en) 2003-03-13
AU2002332838B2 (en) 2007-08-02
WO2003020909A3 (en) 2003-11-20
EP1432446A4 (de) 2004-09-08
IL160659A0 (en) 2004-08-31

Similar Documents

Publication Publication Date Title
WO2020236817A3 (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2020139926A3 (en) Anti-ctla4 antibodies and methods of use thereof
WO2005009389A3 (en) Anaplastic lymphoma kinase modulators and methods of use
UA114879C2 (uk) Антитіло до cd38 для лікування раку
ATE365562T1 (de) Zielgerichtete kombinations-immuntherapie für krebs
NZ596834A (en) Prlr-specific antibody and uses thereof
WO2021090062A8 (en) Anti-mesothelin eribulin antibody-drug conjugates and methods of use
MX2022015374A (es) Conjugados de anticuerpo anti antigeno de maduracion de linfocitos b (bcma)-farmaco y metodos de uso.
MX2022013876A (es) Constructos de anticuerpos triespecificos precursores y metodos de uso de los mismos.
PH12021552790A1 (en) Materials and methods for modulating t cell mediated immunity
MX2021006362A (es) Anticuerpos de dominio simple contra cll-1.
Bachran et al. Epidermal growth factor receptor expression affects the efficacy of the combined application of saponin and a targeted toxin on human cervical carcinoma cells
MX2009001341A (es) Anticuerpos especificos de ephb3 y usos de los mismos.
WO2004089294A3 (en) Compositions, methods and kits relating to her-2 cleavage
MX2022005241A (es) Degradacion de proteinas de superficie usando agente de union biespecifico.
MX2024003779A (es) Agentes de union dirigidos a celulas tumorales que expresan trop2.
DE60239881D1 (de) Verfahren zur identifikation von polypeptid-antigenen im zusammenhang mit störungen durch aberrante zellproliferation
WO2005090406A3 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
WO2021056025A3 (en) Anti-epha10 antibodies and methods of use thereof
WO2023133361A3 (en) Anti-cthrc1 fusion proteins and methods of using the same
WO2022159582A3 (en) Multivalent chlorotoxin chimeric antigen receptors
WO2017171373A3 (ko) Egfr 표적 제제에 대한 저항성을 억제하기 위한 조성물
WO2023169896A8 (en) BINDING MOLECULES AGAINST FRα
WO2023201234A3 (en) Anti-variable muc1* antibodies and uses thereof
EP1629009B8 (de) Zusammensetzungen die grosse und kleine gegen das selbe toxin gerichtete antikkörperfragmente enthalten